These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34418585)

  • 61. Hepatocellular carcinoma and cholangiocarcinoma: an update.
    Yazici C; Niemeyer DJ; Iannitti DA; Russo MW
    Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):63-82. PubMed ID: 24245910
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Fibrolamellar hepatocellular carcinoma.
    Liu S; Chan KW; Wang B; Qiao L
    Am J Gastroenterol; 2009 Oct; 104(10):2617-24; quiz 2625. PubMed ID: 19638962
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Natural history and treatment trends in hepatocellular carcinoma subtypes: Insights from a national cancer registry.
    Jernigan PL; Wima K; Hanseman DJ; Hoehn RS; Ahmad SA; Shah SA; Abbott DE
    J Surg Oncol; 2015 Dec; 112(8):872-6. PubMed ID: 26603598
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular and histological correlations in liver cancer.
    Calderaro J; Ziol M; Paradis V; Zucman-Rossi J
    J Hepatol; 2019 Sep; 71(3):616-630. PubMed ID: 31195064
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients.
    Weeda VB; Aronson DC; Verheij J; Lamers WH
    Pediatr Blood Cancer; 2019 Feb; 66(2):e27475. PubMed ID: 30259629
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers.
    Lee JI; Lee JW; Kim JM; Kim JK; Chung HJ; Kim YS
    World J Gastroenterol; 2012 Sep; 18(34):4751-7. PubMed ID: 23002345
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma.
    Satake T; Shibuki T; Watanabe K; Sasaki M; Imaoka H; Mitsunaga S; Kojima M; Ikeda M
    Front Oncol; 2023; 13():1234113. PubMed ID: 37546425
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets.
    Katoh H; Ojima H; Kokubu A; Saito S; Kondo T; Kosuge T; Hosoda F; Imoto I; Inazawa J; Hirohashi S; Shibata T
    Gastroenterology; 2007 Nov; 133(5):1475-86. PubMed ID: 17983802
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice.
    Liu Y; Xin B; Yamamoto M; Goto M; Ooshio T; Kamikokura Y; Tanaka H; Meng L; Okada Y; Mizukami Y; Nishikawa Y
    Cancer Sci; 2021 Aug; 112(8):3111-3124. PubMed ID: 34051011
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Systemic therapy of advanced hepatocellular carcinoma.
    Galle PR; Dufour JF; Peck-Radosavljevic M; Trojan J; Vogel A
    Future Oncol; 2021 Apr; 17(10):1237-1251. PubMed ID: 33307782
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma.
    Saboo SS; Krajewski KM; Jagannathan JP; O'Regan KN; Odze R; Ramaiya N; Wolpin BM
    Cancer Imaging; 2011 Mar; 11(1):37-41. PubMed ID: 21507775
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-Term Survival of Combined Hepatocellular-Cholangiocarcinoma: A Nationwide Study.
    Chen PD; Chen LJ; Chang YJ; Chang YJ
    Oncologist; 2021 Oct; 26(10):e1774-e1785. PubMed ID: 34213048
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fibrolamellar hepatocellular carcinoma coexistent with a hepatocellular carcinoma of common type: report of a case.
    Okada K; Kim YI; Nakashima K; Tada I; Yoshida T; Kobayashi M; Yokoyama S
    Surg Today; 1993; 23(7):626-31. PubMed ID: 7690275
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma.
    Simon SM
    Nat Rev Cancer; 2023 May; 23(5):335-346. PubMed ID: 36932129
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sarcomatoid hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis.
    Lv TR; Hu HJ; Regmi P; Liu F; Li FY
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1685-1696. PubMed ID: 35201426
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
    Zuo HQ; Yan LN; Zeng Y; Yang JY; Luo HZ; Liu JW; Zhou LX
    Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):161-5. PubMed ID: 17374575
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience.
    Lemekhova A; Hornuss D; Polychronidis G; Mayer P; Rupp C; Longerich T; Weiss KH; Büchler M; Mehrabi A; Hoffmann K
    World J Surg Oncol; 2020 May; 18(1):93. PubMed ID: 32397993
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma.
    Ueno A; Masugi Y; Yamazaki K; Kurebayashi Y; Tsujikawa H; Effendi K; Ojima H; Sakamoto M
    Pathol Int; 2020 Mar; 70(3):140-154. PubMed ID: 31908112
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics.
    Bergquist JR; Groeschl RT; Ivanics T; Shubert CR; Habermann EB; Kendrick ML; Farnell MB; Nagorney DM; Truty MJ; Smoot RL
    HPB (Oxford); 2016 Nov; 18(11):886-892. PubMed ID: 27546172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.